AR038394A2 - Forma de dosificacion oral de liberacion espacialmente retardada - Google Patents
Forma de dosificacion oral de liberacion espacialmente retardadaInfo
- Publication number
- AR038394A2 AR038394A2 ARP030100364A ARP030100364A AR038394A2 AR 038394 A2 AR038394 A2 AR 038394A2 AR P030100364 A ARP030100364 A AR P030100364A AR P030100364 A ARP030100364 A AR P030100364A AR 038394 A2 AR038394 A2 AR 038394A2
- Authority
- AR
- Argentina
- Prior art keywords
- sertraline
- dosage form
- release
- period
- delayed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forma de dosificación oral de liberación retardada de sertralina que disminuye el Tmax en relación con el Tmax de las formas de dosificación de comprimidos de sertralina de liberación inmediata conocidos actualmente, que liberan una dosis en forma de píldora grande equivalente. En lo que se refiere a las formas de dosificación de liberación inmediata, esta también disminuye la incidencia y/o gravedad de los efectos gastrointestinales y/o de otros efectos secundarios. Una forma de dosificación temporalmente retardada adecuada para la administración oral a un mamífero, caracterizada porque comprende (1) un núcleo de liberación inmediata que comprende sertralina o una sal farmacéuticamente aceptable de la misma y un vehículo farmacéuticamente aceptable y (2) un recubrimiento que rodea dicho núcleo, no liberando sustancialmente dicha forma de dosificación, cuando se ensaya en disolución in vitro en un aparato N° 2 de la USP que contiene 900 ml de tampón ácido acético/acetato, pH 4,0, que es NaCl 0,075M, sertralina durante un primer período de aproximadamente 10 minutos, no liberando más del 10 % de la sertralina incorporada en la misma durante un segundo período que dura hasta 2 horas después de dicho período, y efectuando a continuación la liberación inmediata de la sertralina restante incorporada en la misma después de dicho segundo período
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5149997P | 1997-07-01 | 1997-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038394A2 true AR038394A2 (es) | 2005-01-12 |
Family
ID=21971681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100364A AR038394A2 (es) | 1997-07-01 | 2003-02-05 | Forma de dosificacion oral de liberacion espacialmente retardada |
Country Status (41)
| Country | Link |
|---|---|
| EP (1) | EP1007024B1 (es) |
| JP (1) | JP3786715B2 (es) |
| KR (1) | KR100369698B1 (es) |
| CN (4) | CN1475209A (es) |
| AP (1) | AP1199A (es) |
| AR (1) | AR038394A2 (es) |
| AT (1) | ATE245415T1 (es) |
| AU (1) | AU727152B2 (es) |
| BG (1) | BG64742B1 (es) |
| BR (1) | BR9809895A (es) |
| CA (1) | CA2290969C (es) |
| DE (1) | DE69816624T2 (es) |
| DK (1) | DK1007024T3 (es) |
| DZ (1) | DZ2547A1 (es) |
| EA (1) | EA001906B1 (es) |
| ES (1) | ES2202858T3 (es) |
| GT (1) | GT199800091A (es) |
| HK (1) | HK1027982A1 (es) |
| HN (1) | HN1998000099A (es) |
| HR (1) | HRP980376B1 (es) |
| HU (1) | HUP0301787A3 (es) |
| ID (1) | ID23187A (es) |
| IL (2) | IL152304A0 (es) |
| IS (1) | IS5267A (es) |
| MA (1) | MA24585A1 (es) |
| NO (1) | NO996519L (es) |
| NZ (1) | NZ501249A (es) |
| OA (1) | OA11247A (es) |
| PA (1) | PA8454201A1 (es) |
| PE (1) | PE84399A1 (es) |
| PL (1) | PL337799A1 (es) |
| PT (1) | PT1007024E (es) |
| SI (1) | SI1007024T1 (es) |
| SK (1) | SK173299A3 (es) |
| TN (1) | TNSN98122A1 (es) |
| TR (1) | TR199903295T2 (es) |
| TW (1) | TW575437B (es) |
| UA (1) | UA63953C2 (es) |
| UY (1) | UY25068A1 (es) |
| WO (1) | WO1999001122A1 (es) |
| ZA (1) | ZA985710B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL205109B1 (pl) | 1998-11-02 | 2010-03-31 | Elan Pharma Int Ltd | Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie |
| DE60035579T2 (de) * | 1999-05-20 | 2008-04-17 | Elan Corp. Plc | Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme |
| IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
| EE05315B1 (et) | 1999-09-03 | 2010-08-16 | Eli Lilly And Company | Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette nhtud imetajal esineva seksuaalse funktsioonihire ravimiseks v?i m?jutamiseks |
| ES2168043B1 (es) * | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
| KR20030025903A (ko) * | 2000-02-10 | 2003-03-29 | 비피에스아이 홀딩스, 인코포레이션. | 아크릴 장용 코팅 조성물 |
| BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| JP5328071B2 (ja) * | 2001-04-10 | 2013-10-30 | サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド | 時限パルス放出組成物 |
| CA2457385A1 (en) * | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
| GB0607534D0 (en) * | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| EP2586429A1 (en) * | 2011-10-26 | 2013-05-01 | Freund Pharmatec Ltd. | Multi-unit drug delivery device for pulsatile or sustained release |
| CN108014087A (zh) * | 2017-12-27 | 2018-05-11 | 江苏联环药业股份有限公司 | 一种盐酸舍曲林胶囊的制备方法 |
| CN109432038A (zh) * | 2018-12-28 | 2019-03-08 | 乐普制药科技有限公司 | 一种含有盐酸舍曲林的肠溶片剂及其制备方法 |
| CN114129540B (zh) * | 2021-11-19 | 2022-07-05 | 浙江维康药业股份有限公司 | 一种肝苏胶囊及其制作方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| US4803076A (en) * | 1986-09-04 | 1989-02-07 | Pfizer Inc. | Controlled release device for an active substance |
| IL91398A (en) * | 1988-08-30 | 1994-05-30 | Pfizer | A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane |
| EP0357364B1 (en) * | 1988-08-30 | 1993-07-28 | E.I. Du Pont De Nemours And Company | A process for flash-spinning dry polymeric plexifilamentary film-fibril strands |
| US4983401A (en) * | 1989-05-22 | 1991-01-08 | Kinaform Technology, Inc. | Sustained release pharmaceutical preparations having pH controlled membrane coatings |
-
1998
- 1998-06-16 BR BR9809895-0A patent/BR9809895A/pt not_active Application Discontinuation
- 1998-06-16 AU AU75451/98A patent/AU727152B2/en not_active Ceased
- 1998-06-16 ES ES98923022T patent/ES2202858T3/es not_active Expired - Lifetime
- 1998-06-16 DE DE69816624T patent/DE69816624T2/de not_active Expired - Fee Related
- 1998-06-16 WO PCT/IB1998/000937 patent/WO1999001122A1/en not_active Application Discontinuation
- 1998-06-16 CN CNA031489737A patent/CN1475209A/zh active Pending
- 1998-06-16 UA UA99116392A patent/UA63953C2/uk unknown
- 1998-06-16 NZ NZ501249A patent/NZ501249A/en unknown
- 1998-06-16 CN CNA031489729A patent/CN1475208A/zh active Pending
- 1998-06-16 CN CNA200310118311XA patent/CN1494899A/zh active Pending
- 1998-06-16 ID IDW991698A patent/ID23187A/id unknown
- 1998-06-16 EA EA199900965A patent/EA001906B1/ru unknown
- 1998-06-16 CA CA002290969A patent/CA2290969C/en not_active Expired - Fee Related
- 1998-06-16 IL IL15230498A patent/IL152304A0/xx unknown
- 1998-06-16 PT PT98923022T patent/PT1007024E/pt unknown
- 1998-06-16 HU HU0301787A patent/HUP0301787A3/hu unknown
- 1998-06-16 DK DK98923022T patent/DK1007024T3/da active
- 1998-06-16 TR TR1999/03295T patent/TR199903295T2/xx unknown
- 1998-06-16 AT AT98923022T patent/ATE245415T1/de not_active IP Right Cessation
- 1998-06-16 PL PL98337799A patent/PL337799A1/xx unknown
- 1998-06-16 IL IL13308198A patent/IL133081A/xx not_active IP Right Cessation
- 1998-06-16 KR KR10-1999-7011529A patent/KR100369698B1/ko not_active IP Right Cessation
- 1998-06-16 JP JP50677799A patent/JP3786715B2/ja not_active Expired - Fee Related
- 1998-06-16 EP EP98923022A patent/EP1007024B1/en not_active Expired - Lifetime
- 1998-06-16 CN CNB988064294A patent/CN1151783C/zh not_active Expired - Fee Related
- 1998-06-16 SK SK1732-99A patent/SK173299A3/sk unknown
- 1998-06-16 SI SI9830494T patent/SI1007024T1/xx unknown
- 1998-06-25 PA PA19988454201A patent/PA8454201A1/es unknown
- 1998-06-25 AP APAP/P/1998/001278A patent/AP1199A/en active
- 1998-06-25 TW TW087110269A patent/TW575437B/zh active
- 1998-06-26 PE PE1998000577A patent/PE84399A1/es not_active Application Discontinuation
- 1998-06-29 UY UY25068A patent/UY25068A1/es not_active IP Right Cessation
- 1998-06-29 GT GT199800091A patent/GT199800091A/es unknown
- 1998-06-30 TN TNTNSN98122A patent/TNSN98122A1/fr unknown
- 1998-06-30 ZA ZA9805710A patent/ZA985710B/xx unknown
- 1998-06-30 DZ DZ980157A patent/DZ2547A1/xx active
- 1998-06-30 MA MA25144A patent/MA24585A1/fr unknown
- 1998-06-30 HN HN1998000099A patent/HN1998000099A/es unknown
- 1998-07-01 HR HR980376A patent/HRP980376B1/xx not_active IP Right Cessation
-
1999
- 1999-11-23 IS IS5267A patent/IS5267A/is unknown
- 1999-11-23 BG BG103916A patent/BG64742B1/bg unknown
- 1999-12-23 OA OA9900307A patent/OA11247A/en unknown
- 1999-12-28 NO NO996519A patent/NO996519L/no not_active Application Discontinuation
-
2000
- 2000-11-23 HK HK00107492A patent/HK1027982A1/xx not_active IP Right Cessation
-
2003
- 2003-02-05 AR ARP030100364A patent/AR038394A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038394A2 (es) | Forma de dosificacion oral de liberacion espacialmente retardada | |
| AR036768A1 (es) | Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa | |
| PE71699A1 (es) | Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra | |
| AR015919A1 (es) | Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina ,composicion farmaceutica, procedimiento depreparacion y su uso en terapias. | |
| ES2733044T1 (es) | Composición farmacéutica que contiene oxicodona y naloxona | |
| DE69710757D1 (de) | Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe | |
| CA2136411A1 (en) | Immediate Release Tablet Cores of Insoluble Drugs Having Sustained Release Coating | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| ATE30380T1 (de) | Pharmazeutische formulierungen mit mehrfachen einheiten. | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| RU2002113921A (ru) | Препаративные формы гидрокодона с контролируемым высвобождением | |
| CA2126611A1 (en) | Opiod Formulations Having Extended Controlled Release | |
| KR910011257A (ko) | 시메티딘을 함유하는 고체 약제학적 조성물 및 이의 제조방법 | |
| RS115104A (en) | Pramipexole once-daily dosage form | |
| IS4146A (is) | Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara | |
| AR013520A1 (es) | Metodo de preparacion de un dispositivo de administracion transdermal, dispositivo de administracion transdermal y utilizacion de un esteroide comoaditivo en un dispositivo de administracion transdermal | |
| JP2005512995A5 (es) | ||
| JPS63139128A (ja) | Ｌ―ドーパ含有組成物 | |
| KR920703046A (ko) | 경구용 항응고제/혈소판 억제제 저용량 제형 | |
| JP2019172679A5 (es) | ||
| PH20628A (en) | Controlled absorption pharmaceutical formulation | |
| US20240216299A1 (en) | Transmucosal therapeutic system containing agomelatine | |
| UY25234A1 (es) | Formulación de liberación prolongada de venlafaxina | |
| CA2333188C (fr) | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation | |
| LT3119B (en) | Pharmaceutical composition and process for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |